Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments

References

• FordESCroftJBManninoDMWheatonAGZhangXGilesWHCOPD surveillance – United States, 1999–2011Chest2013144128430523619732
   PubMed Web of Science ®Google Scholar
• BosanquetNDeanLIordachescuISheehyCThe effectiveness gap in COPD: a mixed methods international comparative studyPrim Care Respir J201322220921323549383
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management and Prevention of COPD2015 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdfAccessed February 12, 2015
   Google Scholar
• CalverleyPPauwelsRVestboJCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• ZhengJPYangLWuYMThe efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPDChest200713261756176317951625
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• BriggsASpencerMWangHManninoDSinDDDevelopment and validation of a prognostic index for health outcomes in chronic obstructive pulmonary diseaseArch Intern Med20081681717918195198
   PubMed Web of Science ®Google Scholar
• DalalAARobertsMHPetersenHVBlanchetteCMMapelDWComparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20116132221311689
   PubMed Web of Science ®Google Scholar
• BlaisLForgetARamachandranSUse of health care services in patients with chronic obstructive pulmonary disease (COPD) treated with budesonide/formoterol via dry powder inhaler (BUD/FM DPI) versus tiotropium [presented as an oral presentation]Value Health2009123A19
   Web of Science ®Google Scholar
• AstraZeneca PharmaceuticalsComparative effectiveness of symbicort vs spiriva among COPD patientsBethesda, MDNational Library of Medicine2014 Available from: https://clinicaltrials.gov/ct2/show/NCT1917643. ClinicalTrials.gov NLM Identifier: NCT1917643Accessed February 13, 2015
   Google Scholar
• AstraZeneca PharmaceuticalsSYMBICORT Prescribing Information2010 [cited October 24, 2014]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021929s021lbl.pdf
   Google Scholar
• Boehringer Ingelheim PharmaceuticalsSPIRIVA HandiHaler Prescribing Information2011 [cited February 13, 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021395s033lbl.pdf
   Google Scholar
• Bureau of Labor StatisticsSeries CUUR0000SAM22013 Available from: http://www.bls.gov/cpi/home.htmAccessed June 16, 2015
   Google Scholar
• NauDPProportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence2014 Available from: http://www.pqaalliance.org/onAccessed October 20, 2014
   Google Scholar
• AustinPCA critical appraisal of propensity-score matching in the medical literature between 1996 and 2003Stat Med200827122037204918038446
   PubMed Web of Science ®Google Scholar
• AustinPCStatistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity scoreAm J Epidemiol201017291092109720802241
   PubMed Web of Science ®Google Scholar
• ParsonsLSReducing bias in a propensity score matched-pair sample using greedy matching techniquesSAS SUGI 262001214226 Available from: http://www2.sas.com/proceedings/sugi26/p214-26.pdfAccessed August 20, 2015
   Google Scholar
• PasqualeMKSunSXSongFHartnettHJStemkowskiSAImpact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare populationInt J Chron Obstruct Pulmon Dis2012775776423152680
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD00379424214176
   PubMed Web of Science ®Google Scholar
• WelshEJCatesCJPoolePCombination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20135CD00789123728670
   PubMed Web of Science ®Google Scholar
• LoboFSWagnerSGrossCRSchommerJCAddressing the issue of channeling bias in observational studies with propensity scores analysisRes Social Adm Pharm20062114315117138506
   PubMedGoogle Scholar
• PetriHUrquhartJChanneling bias in the interpretation of drug effectsStat Med19911045775812057656
   PubMed Web of Science ®Google Scholar
• Global Initiative for AsthmaGlobal Strategy for Asthma Management and Prevention2014 [updated August 2014; cited February 13, 2015]. Available from: http://www.ginasthma.org/
   Google Scholar
• BefekaduEOnofreiCColiceGLTiotropium in asthma: a systematic reviewJ Asthma Allergy20147112124600237
   PubMedGoogle Scholar
• KerstjensHAEngelMDahlRTiotropium in asthma poorly controlled with standard combination therapyN Engl J Med2012367131198120722938706
   PubMed Web of Science ®Google Scholar
• LeeSWKimHJYooKHLong-acting anticholinergic agents in patients with uncontrolled asthma: a systematic review and meta-analysisInt J Tuberc Lung Dis201418121421143025517806
   PubMed Web of Science ®Google Scholar
• RashidQKleinRTiotropium in the treatment of patients with asthmaSouth Med J2014107533033724937736
   PubMed Web of Science ®Google Scholar
• RodrigoGJCastro-RodriguezJAWhat is the role of tiotropium in asthma?: a systematic review with meta-analysisChest2015147238839625322075
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim PharmaceuticalsSPIRIVA Respimat Prescribing Information2014 [cited February 13, 2015]. Available from: http://www.boehringer-ingelheim.com/products/prescription_medicines/respiratory/asthma/spiriva/public/images/14-3946-Blatter-SPC-Spiriva-ERS.pdf
   Google Scholar
• Boehringer Ingelheim PharmaceuticalsBoehringer Ingelheim Announces U.S. Filing Acceptance of New Drug Application for Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Treatment of Asthma2014 [updated November 3, 2014; cited March 24, 2015]. Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/11-03-14-boehringer-in-gelheim-announces-us-filing-acceptance-new-drug-application-spiriva-respimat-tiotropium-bromide-inhalation-spray-treatment-asthma.html
   Google Scholar